- Email: [email protected]
Asymmetric dimethylarginine (ADMA) and treatment response relationship in male patients with first-episode schizophrenia: Author׳s reply
Psychiatry Research 227 (2015) 371
Contents lists available at ScienceDirect
Psychiatry Research journal homepage: www.elsevier.com/locate/psychres
Letter to the Editor
Asymmetric dimethylarginine (ADMA) and treatment response relationship in male patients with first-episode schizophrenia: Author's reply To the Editors: Firstly, we would like to thank Balta et al. for their valuable contributions. In our study, we have shown that asymmetric dimetylarginine (ADMA) levels in patients with first episode schizophrenia are increased when compared with healthy controls and that ADMA levels are decreased after antipsychotic treatment. High levels of ADMA may be observed in metabolic syndrome, diabetes, hyperlipidemia, hypertension and coronary artery disease as stated by Balta et al. (in press) in their Letter. In our study, to eliminate such effects on ADMA, we have carefully chosen the study group from individuals who have normal urea, creatinine, SGOT, SGPT, hsCRP, cholesterol, triacylglycerol, systolic and diastolic blood pressure and body mass index, as these factors may increase ADMA levels. Nevertheless, we believe that we could not be able to eliminate all causes that may affect ADMA levels in this study.
Besides, as the study covers first episode schizophrenia patients, it is not reasonable to mention tardive dyskinesia or malignant neuroleptic syndrome. Likewise, we can ignore the conditions caused by these patients' circumstances such as unhealthy life style, smoking/drug abuse and low socio-economic level. However, it is important to consider that these variables, which are seen in the prodromal period of these patients, may affect the results of the study. But we have chosen a control group that has similar sociodemographic and clinical features to overcome this handicap. Reference Balta, S., Kurtoglu, E., Bolu, A., Aparci, M., Ozturk, C., 2015. ADMA levels in patients with schizophrenia. Psychiatry Research (in press).
Serkan Zincir n Gölcük Military Hospital, Psychiatry Clinic, Kocaeli 41650, Turkey E-mail address: [email protected] Received 21 February 2015
n
http://dx.doi.org/10.1016/j.psychres.2015.03.039 0165-1781/& 2015 Elsevier Ireland Ltd. All rights reserved.
Cell Phone: þ90 535 349 88 25.
Contents lists available at ScienceDirect
Psychiatry Research journal homepage: www.elsevier.com/locate/psychres
Letter to the Editor
Asymmetric dimethylarginine (ADMA) and treatment response relationship in male patients with first-episode schizophrenia: Author's reply To the Editors: Firstly, we would like to thank Balta et al. for their valuable contributions. In our study, we have shown that asymmetric dimetylarginine (ADMA) levels in patients with first episode schizophrenia are increased when compared with healthy controls and that ADMA levels are decreased after antipsychotic treatment. High levels of ADMA may be observed in metabolic syndrome, diabetes, hyperlipidemia, hypertension and coronary artery disease as stated by Balta et al. (in press) in their Letter. In our study, to eliminate such effects on ADMA, we have carefully chosen the study group from individuals who have normal urea, creatinine, SGOT, SGPT, hsCRP, cholesterol, triacylglycerol, systolic and diastolic blood pressure and body mass index, as these factors may increase ADMA levels. Nevertheless, we believe that we could not be able to eliminate all causes that may affect ADMA levels in this study.
Besides, as the study covers first episode schizophrenia patients, it is not reasonable to mention tardive dyskinesia or malignant neuroleptic syndrome. Likewise, we can ignore the conditions caused by these patients' circumstances such as unhealthy life style, smoking/drug abuse and low socio-economic level. However, it is important to consider that these variables, which are seen in the prodromal period of these patients, may affect the results of the study. But we have chosen a control group that has similar sociodemographic and clinical features to overcome this handicap. Reference Balta, S., Kurtoglu, E., Bolu, A., Aparci, M., Ozturk, C., 2015. ADMA levels in patients with schizophrenia. Psychiatry Research (in press).
Serkan Zincir n Gölcük Military Hospital, Psychiatry Clinic, Kocaeli 41650, Turkey E-mail address: [email protected] Received 21 February 2015
n
http://dx.doi.org/10.1016/j.psychres.2015.03.039 0165-1781/& 2015 Elsevier Ireland Ltd. All rights reserved.
Cell Phone: þ90 535 349 88 25.